SCHEMBL63520

SCHEMBL63520

CN(C)C(=O)C(=O)NC12CCC(CC1)Cn1c2nc(C(=O)NCC2CCCO2)c(O)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
KMT2A Q03164 3/20 0.39
RAB9A P51151 2/20 0.39
MCL1 Q07820 1/20 0.38
GAA P10253 3/20 0.38
ALDH1A1 P00352 8/20 0.37
HPGD P15428 5/20 0.37
NPSR1 Q6W5P4 1/20 0.37
NPC1 O15118 2/20 0.37
HTT P42858 2/20 0.36
HIF1A Q16665 2/20 0.36
GLA P06280 2/20 0.36
LMNA P02545 1/20 0.36
MEN1 O00255 1/20 0.35
HSD17B10 Q99714 3/20 0.35
TSHR P16473 2/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35
CYP2C9 P11712 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63521 0.83 CYP2C9 (0.35) CYP2C9
SCHEMBL64597 0.80 CYP2C9 (0.47) CYP2C9
SCHEMBL64282 0.80 CYP2C9 (0.39) SMN1; SMN2ALDH1A1HPGDHTTLMNA
SCHEMBL62740 0.80 CYP2C9 (0.36) CYP2C9
SCHEMBL64543 0.80 CYP2C9 (0.45) KDM4ESMN1; SMN2ALDH1A1HPGDNPSR1
SCHEMBL63518 0.80 CYP2C9 (0.46) KDM4EKMT2ARAB9AGAAALDH1A1
SCHEMBL63906 0.78 ERCC1 (0.36) SMN1; SMN2RAB9AALDH1A1NPC1CYP2C9
SCHEMBL64541 0.78 CYP2C9 (0.46) KDM4ESMN1; SMN2KMT2ARAB9AALDH1A1
SCHEMBL63535 0.78 CYP2C9 (0.45) KDM4ESMN1; SMN2RAB9AGAAALDH1A1
SCHEMBL52059 0.78 CYP2C9 (0.45) KDM4EALDH1A1LMNACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280981-B1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-04-23 EP disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KDM4E 1609/4885SMN1; SMN2 4431/4885KMT2A 1339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.